Aptorum Group Ltd Dossier
Qualitative Analysis
Business overview
Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) is a clinical-stage biopharmaceutical company historically focused on the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology and infectious diseases. The company's pipeline has included SACT-1 for neuroblastoma and ALS-4 for bacterial infections. However, during fiscal year 2025, Aptorum paused the majority of its research and development activities to focus its attention and resources on completing a strategic business combination.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
An all-stock merger to acquire DiamiR Biosciences Corp., combining Aptorum's clinical-stage biopharmaceutical pipeline with DiamiR's blood-based molecular diagnostics platform for brain health.
Expected impact: Establishes a broader life sciences platform focused on precision medicine, diagnostics, and therapeutics for neurodegenerative and brain health diseases.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To combine Aptorum's clinical-stage therapeutics pipeline with DiamiR's non-invasive, blood-based microRNA diagnostic platform for brain health and aging-related diseases, accelerating commercialization and expanding strategic partnerships.
Financial impact: DiamiR will become a wholly-owned subsidiary of Aptorum. DiamiR stockholders will receive shares representing approximately 70% of the combined company's outstanding common stock, while existing Aptorum shareholders will retain approximately 30%.
Strategic Partnerships
Collaborating to validate INB's automated G8 Genotyping Analyzer for APOE testing against DiamiR's New York State-approved APOE test, aiming to introduce an automated testing solution for Alzheimer's disease risk assessment into clinical practice.
Terms: Terms not publicly disclosed.
Collaborated on a clinical study published in the journal Diagnostics demonstrating the feasibility of detecting glioblastoma (GBM) using specific microRNA signatures in blood plasma as non-invasive biomarkers.
Terms: Terms not publicly disclosed.